Neuralgia

A brief history of Britain's obsession with the hot water bottle

Retrieved on: 
Saturday, December 30, 2023
Bee, Ear, The Herald (Glasgow), Glass, Research, Industry, Heat, Health, Methodism, Neuralgia, Scalding, Boot, Noise, Clothing, Time, Table tennis rubber, Climate, Boots (company), History, Natural rubber

Boiling a kettle to fill a hot water bottle uses less energy than an electric blanket or turning on the heating and so is the cheapest option to keep you warm, according to consumer insights publication Which?.

Key Points: 
  • Boiling a kettle to fill a hot water bottle uses less energy than an electric blanket or turning on the heating and so is the cheapest option to keep you warm, according to consumer insights publication Which?.
  • Feeling the chill ourselves, we have dug into the history of the hot water bottle as part of a large research project on the global history of Boots The Chemists.

The first hot water bottles

  • Hot water bottles have been around in various forms for centuries.
  • These bottles could lose heat quickly and were unpleasant, icy bed companions once cooled.
  • In November 1867, for example, Thornton and Co. promoted their “India Rubber” hot water bottle in the Glasgow Herald, with claims that its product was a “great comfort to invalids”.

Hot water bottles at Boots

  • But they did stock a bewilderingly large range of rubber hot water bottles, carefully tiered by quality and price.
  • While varying in price, all Boots’ hot water bottles were touted to relieve pain as well as provide heat.
  • Because very hot water might crack the rubber, Boots advised its customers to pour a cup of cold water into the bottle first.

An uncomfortable history?

  • Rubber plantation workers in Southeast Asia, for example, often endured harsh conditions to cultivate, tap, and process raw rubber sheets.
  • In the 1920s, Boots staff magazine, The Bee, featured several articles explaining where rubber came from and how hot water bottles were made.
  • Ironically, hot water bottles were often shipped back to rubber-producing countries to help colonial ex-pats deal with the climate.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Richard Hornsey receives funding from the Arts and Humanities Research Council (AHRC). Anna Greenwood receives funding from Arts and Humanities Research Council (AHRC) Hilary Ingram receives funding from the Arts and Humanities Research Council (AHRC)

Hoag Welcomes Renowned Specialist to lead Pain Management Program

Retrieved on: 
Wednesday, August 16, 2023
Diabetic neuropathy, American Academy of Physical Medicine and Rehabilitation, University, Education, Anesthesiology, Diabetes, American Board of Physical Medicine and Rehabilitation, Neuralgia, North American Spine Society, Ageing, Quality of life, Spine, American Society of Interventional Pain Physicians, American Academy, Peripheral neuropathy, Pain, Pain management, American Board of Commissioners for Foreign Missions, Ron, Rehabilitation, Patient, Chronic pain, Accreditation, Accreditation Council, American Board of Anesthesiology, Physical medicine and rehabilitation, Curriculum, Medicine, Nursing, Dentistry

NEWPORT BEACH, Calif., Aug. 16, 2023 /PRNewswire/ -- Hoag is advancing the care and management of pain patients in Orange County with the addition of Charles De Mesa, D.O, M.P.H., who will serve as Chief of Interventional Pain, Physical Medicine & Rehabilitation at the Hoag Spine Center.

Key Points: 
  • He joins the multidisciplinary, specialized team of spine care experts at Hoag to lead and develop the outpatient interventional pain management and rehabilitation services.
  • "His role will expand Hoag's commitment to comprehensive management and continuity of care for patients contending with pain."
  • Dr. De Mesa comes to Hoag from the University of California, Davis, Department of Anesthesiology and Pain Medicine, where he served as the principal investigator in multiple pain management trials.
  • "Pain management is a critical component of what we do at the Hoag Spine Center," said Adam Kanter, M.D., associate executive medical director of the Pickup Family Neurosciences Institute.

Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023
Health, Biotechnology, Chapter Four, Influenza B virus, Central nervous system, Disease, Traumatic brain injury, Sympathetic nervous system, TB, Dizziness, A-Z, Stroke, Research, Directory, Weakness, Orientation, Headache, CNS, Chapter Three, Multiple sclerosis, Vertigo, Chapter One, Restless, Migraine, Chapter Two, Chapter Five, Chapter Six, Collection, Guillain–Barré syndrome, Peripheral neuropathy, Creutzfeldt–Jakob disease, Parkinson's disease, Amyotrophy, Spinal cord, ALS, Cerebral palsy, Hyperlink, Bacteria, Restless legs syndrome, Mycobacterium tuberculosis, Pharmaceutical industry, Music, Bank, Drug, Cryptocurrency, Medical device, Nausea, Haemophilus, Epilepsy, Pain, Neuralgia, Fibromyalgia, Paralysis, Stuttering, Meningitis

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Key Points: 
  • Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
  • Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016.
  • Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, QT, Hypersensitivity, ESR1, Hypocalcemia, Peripheral neuropathy, Anemia, Angioedema, Headache, AstraZeneca, Syncope, Woman, Duane syndrome, Hives, Xeroderma, Paced Auditory Serial Addition Test, Leukopenia, Sciatic nerve, Risk, Indigestion, Thrombocytopenia, Lung, Rash, Myalgia, Liver, Fatigue, Pain, Back pain, US Foods, Photopsia, Birth, Immunoassay, Constipation, Hair, Infant, Infection, Food, Neutropenia, Bleeding, Bradycardia, Pregnancy, Dysgeusia, Cough, Diarrhea, Estradiol, Itch, PFS, Tears, Neuralgia, CI, Purging disorder, Grade, Mutation, Xerostomia, Vertigo, Patient, Fulvestrant, Nausea, Vomiting, Incidence, Aromatase, Breathe Me, Arthralgia, Erythema, Bone pain, Stomatitis, Weakness, Sciatica, Fetus, Neuropathic pain, Appetite, Pharmaceutical industry, Vaccine, Dietary supplement, Fever

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, QT, Indigestion, Thrombocytopenia, ORR, Hypersensitivity, Neutropenia, Rash, Bleeding, Xerostomia, Pregnancy, Dysgeusia, Cough, Hypocalcemia, Vertigo, Patient, Diarrhea, Peripheral neuropathy, Estradiol, OS, Myalgia, Anemia, Liver, Angioedema, Itch, Nausea, Fulvestrant, Neuralgia, Headache, Tears, Fatigue, Vomiting, Syncope, Pain, Back pain, Appetite, Breathe Me, Woman, Incidence, Arthralgia, Erythema, Bone pain, Birth, Stomatitis, Duane syndrome, Hives, Immunoassay, Constipation, Safety, Purging disorder, Hair, Xeroderma, Infant, Sciatica, Weakness, Paced Auditory Serial Addition Test, Infection, Fetus, Leukopenia, AES, Neuropathic pain, Sciatic nerve, Risk, Medical imaging, Vaccine, Dietary supplement, Fever

CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.

Key Points: 
  • CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.
  • Capivasertib is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for hematologic malignancies.
  • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION).
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Other Health, Parkinson's disease, Restless legs syndrome, Disease, CNS, Directory, Technology, Dizziness, SEC, Finance, Chapter Four, Multiple sclerosis, Chapter Five, Central nervous system, Chapter Three, Haemophilus influenzae, Restless, Guillain–Barré syndrome, Review, Stroke, Contract, Traumatic brain injury, Amyotrophy, Players, Bacteria, Peripheral neuropathy, Weakness, Chapter Six, Cerebral palsy, Chapter One, Chapter Two, Vertigo, Hyperlink, Migraine, Peripheral nervous system, Spinal cord, Creutzfeldt–Jakob disease, Headache, Mycobacterium tuberculosis, Sclerosis (medicine), TB, A-Z, Pharmaceutical industry, Bank, Risk management, Petroleum, Nausea, Stuttering, Fibromyalgia, Meningitis, Epilepsy, Paralysis, Neuralgia, Pain, Haemophilus

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by:

Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Birth, Toxicity, Multiple myeloma, Lymphocytopenia, Dehydration, Mannitol, Female, Thrombocytopenia, CEO, Nausea, Risk, Bortezomib, MRI, Mantle cell lymphoma, Fresenius (company), Peripheral neuropathy, Patient, Thrombotic microangiopathy, Program, Heart, FDA, Incidence, Industry, Diabetes, Constipation, Vomiting, Anaphylaxis, Injection, Cardiotoxicity, Fatigue, Diarrhea, Mantle, Internet, Tumor lysis syndrome, Purging disorder, Multimedia, Fetus, Neuralgia, LLC, Blood, Degenerative disease, Boron, Leukopenia, Cancer, Hypersensitivity, Hypotension, Anemia, Rash, Severe acute respiratory syndrome, Adult, MD Anderson Cancer Center, Science, Pharmaceutical industry, Vaccine, Health insurance, Medical device, Medical imaging, Birth control, Online gambling, Neutropenia, Fever

Fresenius Kabi Bortezomib for Injection is an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma .

Key Points: 
  • Fresenius Kabi Bortezomib for Injection is an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma .
  • Were pleased to be able to provide an affordable option to patients and we are especially pleased that Fresenius Kabi Bortezomib for Injection is produced at one of our U.S. facilities.
  • To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • Fresenius Kabi ( www.fresenius-kabi.com/us ) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition.

P2X Purinoceptor 3 (P2RX3) - Global Therapeutic Landscape Assessment, 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 16, 2022
Health, Pharmaceutical, Visceral pain, Health, P2RX3, Neuropathic pain, R, Pre-registration house officer, Alzheimer's disease, Target, Central nervous system, Low back pain, Disease, Therapy, Obstructive sleep apnea, Women's health, ROA, Mall of America, Ocular hypertension, Neuralgia, Discovery, Overactive bladder, Fine chemical, Itch, P2X, Cough, Pain, Insomnia, Ophthalmology, Dermatology, Endometriosis

The "P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules.
  • The report outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

2021 Global Central Nervous System Partnering Directory: Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 4, 2022
Health, General Health, CNS, Dizziness, Disease, Central nervous system, Players, Peripheral neuropathy, Haemophilus influenzae, Restless, Stroke, Headache, A-Z, Creutzfeldt–Jakob disease, Migraine, Contract, Traumatic brain injury, Mycobacterium tuberculosis, Parkinson's disease, Guillain–Barré syndrome, Research, Hyperlink, Finance, Amyotrophy, Sclerosis (medicine), Multiple sclerosis, Restless legs syndrome, Bacteria, Weakness, Biotechnology, Technology, Cerebral palsy, Collection, Peripheral nervous system, Spinal cord, Vertigo, TB, Cryptocurrency, Pharmaceutical industry, Paralysis, Pain, Meningitis, Epilepsy, Haemophilus, Fibromyalgia, Stuttering, Neuralgia, Nausea

The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Central Nervous System Partnering 2014 to 2010 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • In Global Central Nervous System Partnering 2014 to 2021, available deals and contracts are listed by:

Thailand Establishes the International Medical Cannabis Research Center

Retrieved on: 
Monday, November 22, 2021
Patient, Amara, Movement, Time, Cannabis, Neuralgia, Multiple sclerosis, Partnership, WHO, Cancer, Myalgia, COVID-19, MOU, Policy, US, Research, Investment, Genetics, Seizure, Dietary supplement, Alternative, Public health, Food, Multimedia, Farmer, Epilepsy, Cosmetics, Medicinal plants, Drug

BANGKOK, Nov. 22, 2021 /PRNewswire/ -- Thailand's Public Health Ministry has signed a Memorandum of Understanding (MOU) with RxLeaf World Medica on establishing the International Medical Cannabis Research Center.

Key Points: 
  • BANGKOK, Nov. 22, 2021 /PRNewswire/ -- Thailand's Public Health Ministry has signed a Memorandum of Understanding (MOU) with RxLeaf World Medica on establishing the International Medical Cannabis Research Center.
  • The center aims to be a knowledge hub for genetic research on medical cannabis, bringing together doctors, researchers, experts from Canada, the Netherlands and other countries to conduct cannabis products research and development while at the same time exchanging the medical cannabis knowledge.
  • Mr. Anutin Charnvirakul, Deputy Prime Minister of Thailand and Minister of Public Health, said the ministry has been promoting medical cannabis and its safe treatment.
  • This policy led to a partnership between public and private sectors in establishing the International Medical Cannabis Research Center under an MOU signing with RxLeaf World Medica Company Limited, a subsidiary of Amara Asia Company Limited .